Array BioPharma, Amgen reach deal on diabetes drug
Colorado research biotech Array BioPharma Inc. has reached a deal with industry giant Amgen Inc. that gives $60 million to Array and separately funds research jobs at the company.
The Boulder-based company licensed continued development of an experimental Type II diabetes drug, ARRY-403, to Amgen in exchange for the $60 million up front. Amgen also agreed to pay for an undisclosed number of research jobs at Array for two years.
Array BioPharm will complete the Phase I trial it started this year on ARRY-403, testing its safety and dosing in people for the first time. Under the licensing arrangement, Thousand Oaks, Calif.-based Amgen, will conduct future testing and development of the drug.
Under the terms of the deal, Array BioPharma retains the right to co-promote the drug in the United States, if ARRY-403 makes it to market. It will also make royalties on future sales of ARRY-403 that Amgen makes, the companies announced Monday evening.
With 390 employees, Array is second in size only to Amgen among Colorado’s commercial biotech drug employers, and the largest one based in the state. Amgen employs about 900 people in Boulder County.
Array researchers struck upon developing "glucokinase activator" compounds for treating diabetes in 2005 Same day payday loans. ARRY-403, the leading drug resulting from the research, is hoped to be a once-a-day pill that helps the body modulate glucose levels in the blood and increases the production of insulin, a process that doesn’t work properly in diabetics.
"Amgen is a leading innovator of important new therapies, with a focus on the treatment of severe, chronic diseases, and we believe that this collaboration indicates the significant potential of our glucokinase activator program," said Array CEO Robert Conway in a press release.
A trio of former Amgen scientists launched Array BioPharma in 1998 after Amgen closed some of its Boulder labs there. Array started with 25 employees and grew by researching potential drug compounds — primarily potential cancer treatments — for other biotechs.
ARRY-403 is among the first generation of treatments Array started developing for itself.
The Amgen deal helps Array end the year with positive news after it laid off 40 employees in January and scaled back its research focus.